Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Mark Cobbold1_Carsten Linnemann2 _2023
VIEWPOINTS

Mark Cobbold and Carsten Linnemann Share Insights on Neogene Therapeutics’ Acquisition

Shots: Carsten gave the details of the agreement with Neogene Therapeutics to bring cell therapies to patients with solid tumors through Neogene’s next-generation T-cell receptor therapies. He also talked about Neogene’s TCR discovery platform Mark spoke about how this acquisition provides AstraZeneca with a unique opportunity to bring innovative science and leading experts in T-cell…
May 4, 2023

Read more

Viewpoints_Carsten Linnemann
VIEWPOINTS

Carsten Linnemann, CEO at Neogene Therapeutics Shares Insights on the Approval of CTA for the P-I Trial of its TCR Therapy to Treat Solid Tumors

Carsten spoke about the approval of CTA by the Dutch regulatory authority for a P-I study evaluating its TCR therapy for the treatment of solid tumors Carsten also emphasized how NT-125 will be different from other TCR therapies The interview shows the advancement of Neogene’s pipeline developing transformative TCR therapies targeting neoantigens in solid cancers…
September 7, 2022

Read more